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Online License and Registration 
Renewals
The Iowa Board of Pharmacy has converted its legacy 
licensing database to iGov Solutions, LLC’s Integrated 
Licensing and Enforcement Management System (iLEMS). 
You may now log on at https://iowa.igovsolution.com/ibop 
online/user_login.aspx and create a user profile. Through this 
portal, individuals can manage personal information online, 
including updating address and employment information.
A cornerstone to this solution includes the provision for 
licensees and registrants to renew and pay for licenses and 
registrations online through their respective user profiles. 
As of May 15, 2018, pharmacists, pharmacy technicians, 
and individual Controlled Substance Act (CSA) registrants 
are able to renew through the online portal. More license 
and registration categories will be added and given online 
renewal permissions throughout 2018. Businesses will be 
able to renew licenses online starting November 1, 2018.
Approved Activities: Technicians vs 
Interns
By Danielle Watznauer, Pharmacist-Intern 
Often there may be confusion as to what the differences are 
regarding what pharmacy technicians and pharmacist-interns 
may do within the pharmacy. The greatest difference lies 
within activities entailing professional judgment. Pharmacy 
technicians are not authorized to perform tasks requiring 
professional judgment. Such activities include interpreting 
prescription drug orders, conducting prospective drug use 
review, and performing final product verification, except 
for participation in an approved tech-check-tech program. 
Technicians cannot provide patient counseling, consultation, 
or patient-specific drug information, nor can they tender 
an offer of patient counseling on behalf of a pharmacist 
or accept a refusal of patient counseling from a patient or 
patient’s agent. They also cannot transfer a prescription to 
another pharmacy or receive the transfer of a prescription 
from another pharmacy.
However, pharmacist-interns are allowed to perform 
activities requiring professional judgment. These tasks, 
usually restricted to a pharmacist, may be delegated to interns 
registered by the Board at the discretion of the supervising 
pharmacist. These judgmental functions include, but are not 
limited to, verifying the accuracy, validity, and appropriate-
ness of filled prescriptions, reviewing and assessing patient 
records, providing patient counseling, and administering 
vaccinations. In addition, interns may answer patient-specific 
drug information questions and transfer a prescription into or 
out of the pharmacy under the pharmacist’s supervision. A 
licensed pharmacist on duty in the pharmacy is responsible 
for all actions of the intern.
Prescription Monitoring Program – 
Updated!
By Sharon Smith, Clerk Specialist
On April 4, 2018, the Board, in coordination with Appriss 
Health, launched its new prescription monitoring program 
(PMP) system, PMP AWARXE. The updated, more user-
friendly software platform allows users the ability to register 
and submit requests online, self-manage delegate users, and 
reset their own password, to name a few small but conve-
nient changes. The new advanced analytical tool, NarxCare, 
primarily uses PMP data to generate a patient-centered 
interactive report, including Narx Scores and Overdose Risk 
Scores, which enables prescribers and dispensers to visual-
ize and analyze their patients’ controlled substance (CS) use 
history. This, along with the optional integration into elec-
tronic health records and pharmacy dispensing systems, will 
make the PMP an even greater asset to health care profession-
als when determining appropriate treatment for their patients.
Additionally, dispensers can now submit data to multiple 
states with one PMP Clearinghouse account. On May 16, 
2018, Board Rule 657-37.3(3) became effective, which re-
quires dispensers to report dispensings to the PMP no later 
than the next business day. 
Technical assistance provided by Appriss Health is avail-
able 24/7 at 844/442-4767. More information regarding 
PMP AWARxE may be found at https://iowa.pmpaware.net. 
drugs or press it into counterfeit prescription pills, often 
without users’ awareness, which leads to overdose inci-
dents, notes the 2017 NDTA. To access the 2017 NDTA, 
visit www.dea.gov/divisions/hq/2017/hq102317.shtml.
FDA Recognizes Eight European Drug 
Regulatory Authorities Capable of 
Conducting Inspections
FDA has determined it will recognize eight European 
drug regulatory authorities as capable of conducting 
inspections of manufacturing facilities that meet FDA 
requirements. The eight regulatory authorities found to be 
capable are those located in Austria, Croatia, France, Italy, 
Malta, Spain, Sweden, and the United Kingdom. This 
achievement marks an important milestone to successful 
implementation and operationalization of the amended 
Pharmaceutical Annex to the 1998 US-European Union 
(EU) Mutual Recognition Agreement, which enables US 
and EU regulators to utilize each other’s good manufactur-
ing practice inspections of pharmaceutical manufacturing 
facilities. “By partnering with these countries, we can 
create greater efficiencies and better fulfill our public 
health goals, relying on the expertise of our colleagues 
and refocusing our resources on inspections in higher risk 
countries,” said FDA Commissioner Scott Gottlieb, MD, 
in a news release located at www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm583057.htm. 
Incorrect Use of Insulin Pens at Home 
Can Cause Severe Hyperglycemia
The National Coordinating Council for Medication 
Error Reporting and Prevention has issued an alert on 
the incorrect use of insulin pens at home causing severe 
hyperglycemia in patients, including one reported fatal-
ity. The Institute for Safe Medication Practices National 
Medication Errors Reporting Program has received sev-
eral reports of patients who failed to remove the inner 
cover of standard insulin pen needles prior to admin-
istering insulin. In the latest such event, a patient with 
type 1 diabetes did not know to remove the standard needle 
cover and was unaware she was using the pen incorrectly 
and had not been receiving any of the insulin doses; the 
patient developed diabetic ketoacidosis as a result and 
died. 
Since insulin pens may differ between pens with 
automatic needle retraction devices and those with stan-
dard needle covers that require manual removal before 
administering insulin, it is imperative that removal of 
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FDA Requires Labeling Update on 
Opioid-Containing Cough and Cold 
Medicines
In January 2018, Food and Drug Administration (FDA) 
announced that the agency is requiring safety labeling 
changes to limit the use of prescription opioid cough 
and cold medicines containing codeine or hydrocodone 
in children younger than 18 years old because the seri-
ous risks of these medicines outweigh their potential 
benefits in this population. After safety labeling changes 
are made, these products will no longer be indicated for 
use to treat cough in any pediatric population and will 
be labeled for use only in adults aged 18 years and older. 
In addition, labeling for the medications will be updated 
with additional safety information for adult use. This up-
date will include an expanded Boxed Warning notifying 
consumers about the risks of misuse, abuse, addiction, 
overdose and death, and slowed or difficult breathing 
that can result from exposure to codeine or hydroco-
done. Additional information is available in FDA’s news 
release at www.fda.gov/NewsEvents/Newsroom/Press 
Announcements/ucm592109.htm.
Latest NDTA Shows Opioids Pose 
Significant Impact to Public Health
Drug Enforcement Administration (DEA) indicates a 
significant shift in the overall drug threat reported by law 
enforcement over the last 10 years with opioids (including 
controlled prescription drugs, fentanyl and other synthetic 
opioids, and heroin) reaching epidemic levels and impact-
ing significant portions of the United States. According 
to the 2017 National Drug Threat Assessment (NDTA) 
report, every year since 2001, controlled prescription 
drugs, specifically opioid analgesics, have been linked to 
the largest number of overdose deaths of any illicit drug 
class, outpacing those for cocaine and heroin combined. 
From 2007 to 2010, responses to the National Drug 
Threat Survey indicate cocaine was the greatest national 
drug threat, followed by a significant decline as the her-
oin threat increased between 2010 and 2016, eventually 
becoming the greatest national drug threat in 2015. 
Illicit fentanyl and other synthetic opioids, primarily 
sourced from China and Mexico and shipped directly to 
the US or trafficked overland via Mexico and Canada, 
are contributing factors in the current synthetic opioid 
overdose epidemic. Traffickers in the US usually mix 
fentanyl into heroin products and sometimes other illicit 
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needle covers be explained to patients who are issued 
standard insulin pens during their diabetes education. 
Pharmacists should verify that a patient understands the 
appropriate administration technique whenever pens 
and insulin needles are dispensed, notes the alert, which 
can be viewed at www.nccmerp.org/sites/default/files/ 
nan-20171012.pdf.
FDA Advises on Opioid Addiction 
Medications and Benzodiazepines
Opioid addiction medications – buprenorphine and 
methadone – should not be withheld from patients taking 
benzodiazepines or other drugs that depress the central 
nervous system (CNS), advises FDA. The combined use 
of these drugs increases the risk of serious side effects; 
however, the harm caused by untreated opioid addic-
tion usually outweighs these risks. Careful medication 
management by health care providers can reduce these 
risks, notes a safety alert. FDA is requiring this informa-
tion to be added to the buprenorphine and methadone drug 
labels along with detailed recommendations for minimiz-
ing the use of medication-assisted treatment drugs and 
benzodiazepines together. 
Health care providers should take several actions and 
precautions and should develop a treatment plan when 
buprenorphine or methadone is used in combination 
with benzodiazepines or other CNS depressants. Addi-
tional information may be found at www.fda.gov/Drugs/ 
DrugSafety/ucm575307.htm.
Only About 3% of Pharmacies and Other 
Entities Voluntarily Maintain a Prescription 
Drug Disposal Bin, GAO Reports
In response to the US Senate Judiciary Committee’s 
request to review DEA’s requirements for authorized 
collectors of prescription drugs and participation rates, the 
US Government Accountability Office (GAO) found that 
only about 3% of pharmacies and other entities eligible to 
collect unused prescription drugs for disposal have vol-
unteered to do so. As of April 2017, 2,233 of the 89,550 
eligible entities had registered with DEA to use disposal 
bins to collect unused prescription drugs. The majority 
of the authorized collectors were pharmacies, followed 
by hospitals or clinics. Factors that affected voluntary 
participation in maintaining disposal bins for the public 
included cost, uncertainty of proper implementation, and 
participation in other drug disposal efforts. 
GAO found that participation rates varied by state. 
Connecticut, Missouri, and Maine had the lowest par-
ticipation rates as of April 2017. North Dakota had the 
highest participation rate, followed by Alaska. The report, 
Preventing Drug Abuse: Low Participation by Pharma-
cies and Other Entities as Voluntary Collectors of Unused 
Prescription Drugs, is located on the GAO website at 
www.gao.gov/products/GAO-18-25.
One in Five Drivers Uses a Prescription 
Drug That Can Impair Driving Despite 
Receiving Warnings
A new study that analyzes data from the National Road-
side Survey of Alcohol and Drug Use, 2013-2014, found 
that one in five drivers has taken prescription drugs that 
could impair driving despite having been warned about 
the risks. The authors of the study, “Receipt of Warnings 
Regarding Potentially Impairing Prescription Medications 
and Associated Risk Perceptions in a National Sample 
of U.S. Drivers,” indicate that of the 7,405 random driv-
ers who completed the prescription drug portion of the 
survey, almost 20% reported recent use (within the past 
two days) of a potentially impairing prescription drug. 
Compared to people who were prescribed antidepres-
sants (62.6%) and stimulants (57.7%), those who were 
prescribed sedatives (85.8%) and narcotics (85.1%) were 
most likely to report receiving warnings about the poten-
tial of these drugs to affect driving from their health care 
provider, pharmacy staff, or medication label. 
Several European countries have introduced color-
coded categories (ie, no, minor, moderate, and major 
influence on driving) to drug labeling to increase patient 
safety. Beyond labeling, the authors of the study note 
it is important that health care providers consistently 
communicate with patients about their medications’ 
driving-related risks. The study was published online in 
the Journal of Studies on Alcohol and Drugs on October 
31, 2017, and can be found at https://doi.org/10.15288/
jsad.2017.78.805.
PTCB CPhT Program Earns Accreditation 
From the American National Standards 
Institute
The Pharmacy Technician Certification Board’s 
(PTCB’s) Certified Pharmacy Technician (CPhT) 
Program has earned accreditation from the American 
National Standards Institute (ANSI) Personnel Certifi-
cation Accreditation Program through December 2022. 
ANSI is the first personnel certification accreditation 
body in the US to meet internationally accepted practices 
for accreditation. “We were the first pharmacy techni-
cian certification program to receive accreditation by the 
National Commission for Certifying Agencies (NCCA) 
in 2006, and now we are the first and only program to 
achieve ANSI accreditation,” said PTCB Executive 
Director and Chief Executive Officer William Schimmel 
in a news release. More details are available in PTCB’s 
December 18, 2017 news release, which can be found in 
the News Room section of www.ptcb.org.
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 USP Chapters <795> and <797> Updates 
on Compounding Standards – Comment 
Period
To provide a unified approach to quality compounding, 
United States Pharmacopeia (USP) intends to align the 
timing and content of General Chapters <795>, <797>, and 
<800>. Chapters <795> and <797> are in the active revision 
process. Among other content changes in the proposed revi-
sions, hazardous drug handling sections in Chapters <795> 
and <797> will reference Chapter <800>. Chapter <800> 
was completed and published in February 2016 and is not 
currently under revision. 
The three chapters are anticipated to be official and aligned 
on December 1, 2019. It is important to note that the current 
published versions of United States Pharmacopeia and the 
National Formulary Chapters <795> and <797> are official 
until the revised chapters become official.
The public comment period for Chapter <795> opened on 
March 30, 2018, and will close on July 31, 2018. Comments 
may be submitted electronically at https://usp.az1.qualtrics 
.com/jfe/form/SV_aWexhZowjRBbKnP. The public comment 
period for Chapter <797> will open on July 27, 2018, and 
will close on November 30, 2018. USP will host an open 
microphone session on September 5, 2018. During the ses-
sion, USP will highlight changes in the proposed revised 
standard and answer questions about the approach and 
methodology of the revision. 
As a reminder, the Board requires adherence to USP Chap-
ter <795>  (Board Rule 657-20.3) and Chapter <797> (Board 
Rule 657-20.4). Questions regarding compliance standards 
may be directed to your assigned compliance officer.
Legislative Update
By Dayton Trent, Pharmacist-Intern
The Iowa Legislature has adjourned its 2018 session. 
The Legislature passed a significant bill relating to the 
opioid epidemic (House File 2377, referred to as the “opioid 
bill”), as well as bills initiated by the Board and the Iowa 
Pharmacy Association (IPA). On  May 14, 2018, Governor 
Kim Reynolds signed the opioid bill; she has also signed the 
Board’s and IPA’s bills.
House File 2377 was signed into law with hopes to mitigate 
the opioid epidemic. The bill contains several new require-
ments, but the information below covers only the portions 
that affect pharmacists and pharmacies:
Electronic Prescriptions. Beginning January 1, 2020, 
every prescription issued must be electronically transmitted 
to a pharmacy. There are certain exceptions identified in the 
bill – such as for patients residing in inpatient hospice care, 
long-term residential facilities, or correctional facilities – 
and exemptions for licensed veterinarians or practitioners 
who are unable to timely comply (with Board approval). 
A pharmacist who receives a written, oral, or facsimile 
prescription after January 1, 2020, will not be required to 
verify that a prescription is subject to an exception and may 
still dispense the medication. However, a pharmacist must 
exercise professional judgment in identifying and reporting 
suspected violations to the Board or to the appropriate pro-
fessional licensing board.
PMP Reporting. The bill requires dispensers to report 
to the PMP the dispensing of opioid antagonists in addition 
to the other CS previously required. The bill also removes a 
previous exemption and will require, as of July 1, 2018, the 
reporting of CS dispensing for inpatient hospital patients.
CSA Registration Surcharge. The Board may add a 
surcharge of not more than 25% to a CSA registration ap-
plication fee to fund the PMP.
PMP Proactive Notification/Prescriber Activity 
Reports. The bill allows the Board to distribute proactive 
notifications to prescribers or pharmacists that will indicate 
when a patient may be doctor shopping or pharmacy shop-
ping or is at risk of abusing or misusing a CS. The Board 
will also better educate prescribers with annual prescriber 
activity reports beginning by February 1, 2019.
Senate File (SF) 2298 was passed by both houses and 
signed by the governor on May 16, 2018. The bill modifies 
the composition of the Board by adding a registered, certi-
fied pharmacy technician to the Board membership. The 
bill also addresses the licensure of wholesale distributors to 
align with federal law and creates a new licensure category 
for third-party logistics providers.
SF 2322 was also passed by both houses and signed by the 
governor on May 16, 2018. The bill allows technician product 
verification programs to be initiated in community pharma-
cies and allows the establishment of statewide protocols for 
certain services (such as immunizations), both pursuant to 
the enactment of rules by the Board.
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